TKI concurrent with cerebral radiation therapy Dutch: TKI tegelijkertijd met bestraling van de hersene

Recruiting

• Conditions: neurotoxicity<br /><br />niet-kleincellig longkanker; hersenmetastasen; bestraling van de hersenen; concurrent treatment; SCLC; brain metastases; gelijktijdige behandeling; cranial radiotherapy; neurotoxiciteit

• Registration Number: NL-OMON28884
• Lead Sponsor: Maastricht UMC+<br>PO Box 5800 6202 AZ Maastricht<br>The Netherlands

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 28 February 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 140

Inclusion Criteria

To be eligible to participate in this study, a patient must meet all of the following criteria:

-Stage IV NSCLC with driver mutation, treated with TKI, development of brain metastases during TKI treatment

Exclusion Criteria

A potential patient who meets any of the following criteria will be excluded from participation in this study:

-Prior radiotherapy to the brain when this precludes new radiotherapy.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Increase in incidence of acute severe toxicity (per TKI) 2 weeks after completion of cranial radiotherapy, measured with CTCAE v 4.0, compared to baseline data<br><br /><br /><br>Increase in neurotoxicity 4 months after completion of cranial radiotherapy compared to baseline data

Secondary Outcome Measures

Name	Time	Method
Increase in neurotoxicity 6 months after completion of cranial radiotherapy compared to baseline data.